

Supplementary Table 1: List of completed and ongoing clinical trials using agonistic CD40 antibodies

Database identifier	Tumor type	Setting	Phase	Treatment arms	Target accrual	Status	Reference
NCT02225002	solid tumors	advanced disease	I	CP-870,893 (single dose)	29	completed	38
NCT02157831	solid tumors	advanced disease	I	CP-870,893 (weekly dose)	27	completed	39
NCT00607048	solid tumors	1 <sup>st</sup> line, advanced disease	I	CP-870,893 + carboplatin/paclitaxel	34	completed	40
ACTRN12609000294257	pleural mesothelioma	1 <sup>st</sup> line, advanced disease	I	CP-870,893 + cisplatin/premetexed	15	completed	42
NCT00711191	pancreatic adenocarcinoma	1 <sup>st</sup> line, chemotherapy-naïve, surgically uncurable disease	I	CP-870,893 + gemcitabine	22	completed	25,41
NCT01456585/ NCT02588443	pancreatic adenocarcinoma	1 <sup>st</sup> line, resectable tumors	I	1. neoadjuvant CP-870,893 2. neoadjuvant CP-870,893 + gemcitabine/nab-paclitaxel both arms: adjuvant CP-870,893 + gemcitabine/nab-paclitaxel	10	completed	
NCT01103635	melanoma	metastatic disease	I	CP-870,893 + tremelimumab (anti-CTLA- 4)	32	completed	43
NCT01008527	melanoma	stage III or IV	I	CP-870,893 + peptid vaccine + poly IC:LC	22	completed	

NCT02760797	solid tumors	advanced disease, with no other effective therapy option available	I	RO7009789 + emactuzumab (anti-CSF1R)	38	recruitment completed	
NCT02304393	solid tumors	locally advanced/ metastatic disease, with no other effective therapy option available	I	1. selicrelumab i.v. + atezolizumab (anti-PD-L1) 2. selicrelumab s.c. + atezolizumab (anti-PD-L1)	230	active	
NCT02665416	solid tumors	metastatic disease, with no other effective therapy option available	I	1. selicrelumab + vanucizumab (anti-Ang2) 2. selicrelumab + bevacizumab (anti-VEGF)	170	active	
NCT01561911	CD40-expressing solid tumors and lymphoma	advanced disease, with no other effective therapy option available	I	ChiLob 7/4 (weekly dose)	29	completed	52
NCT02482168	1. solid tumors 2./3. urothelial carcinoma, melanoma, squamous cell carcinoma of the head and neck, NSCLC, or any solid tumor with high microsatellite instability status (MSI-high)	patients with no other effective therapy option available	I	1. APX005M (every 3 weeks) 2. APX005M (every 2 weeks) 3. APX005M (every 1 week)	43	recruitment completed	

NCT03389802	1. primary malignant pediatric CNS tumors ex diffuse intrinsic pontine glioma (DIPG) 2. DIPG	1. recurrent or refractory disease 2. newly diagnosed	I	APX005M (every 3 weeks)	45	recruiting	
NCT03214250	pancreatic adenocarcinoma	untreated metastatic disease	I/II	1. APX005M + gemcitabine + nab-paclitaxel 2. APX005M + gemcitabine + nab-paclitaxel + nivolumab	105	recruiting	
NCT03719430	soft tissue sarcoma	uncurable disease	II	APX005M + doxorubicin + olaratumab (anti-PDGFR $\alpha$ )	27	recruiting	
NCT03165994	esophageal carcinoma, gastroesophageal carcinoma	resectable, previously untreated disease	II	Neoadjuvant APX005M + radiation therapy + carboplatin + paclitaxel	16	recruiting	
NCT03123783	1. NSCLC 2. melanoma	1. immunotherapy naïve advanced or metastatic disease, which progressed under chemotherapy/ targeted therapy 2. unresectable or metastatic disease which progressed under PD-1/PDL-1 treatment	I/II	APX005M + nivolumab (anti-PD1)	100	recruiting	

NCT02706353	melanoma	metastatic disease	I/II	APX005M (injected intratumorally) + pembrolizumab (anti-PD1)	41	recruiting	
NCT03597282	melanoma	advanced or metastatic, previously untreated disease	I	<ol style="list-style-type: none"> <li>1. APX005M + NEO-PV-01 + poly IC:LC + nivolumab</li> <li>2. APX005M + NEO-PV-01 + poly IC:LC</li> <li>3. APX005M + nivolumab</li> <li>4. NEO-PV-01 + poly IC:LC + nivolumab</li> <li>5. NEO-PV-01 + poly IC:LC + nivolumab (alternate schedule)</li> <li>6. nivolumab + poly IC:LC</li> <li>7. NEO-PV-01 + poly IC:LC + nivolumab + ipilimumab (anti-CTLA-4)</li> <li>8. nivolumab + ipilimumab</li> </ol>	40	recruiting	
NCT03502330	NSCLC melanoma renal cell carcinoma	uncurable disease, which progressed under PD-1/PD-L1 treatment	I	<ol style="list-style-type: none"> <li>1. APX005M + cabiralizumab (anti-CSF1R)</li> <li>2. APX005M + cabiralizumab + nivolumab</li> </ol>	120	recruiting	
NCT02379741	solid tumors	advanced disease	I	<ol style="list-style-type: none"> <li>1. ADC-1013 i.v.</li> <li>2. ADC-1013 (injected intratumorally)</li> </ol>	24	completed	49

NCT02829099	solid tumors	advanced disease	I	JNJ-64457107	114	recruiting	
NCT02376699	malignancies including 1. solid tumors and 2. lymphoma	advanced disease	I	1. SEA-CD40 i.v. 2. SEA-CD40 i.v. + pembrolizumab (only for solid tumors) 3. SEA-CD40 s.c.	95	recruiting	
NCT03329950	solid tumors	advanced disease, which failed all standard of care treatments	I	1. CDX-1140 2. CDX-1140 + CDX340 (recombinant human FMS-like tyrosine kinase-3 ligand (Flt3L))	140	recruiting	
NCT02955251	solid tumors, NSCLC	advanced disease	I	1. ABBV-428 2. ABBV-428 + nivolumab	172	recruiting	